Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
3.830
-0.540 (-12.36%)
At close: Apr 1, 2025, 4:00 PM
4.087
+0.257 (6.70%)
After-hours: Apr 1, 2025, 4:11 PM EDT
Adverum Biotechnologies Employees
Adverum Biotechnologies had 121 employees as of December 31, 2023. The number of employees decreased by 2 or -1.63% compared to the previous year.
Employees
121
Change (1Y)
-2
Growth (1Y)
-1.63%
Revenue / Employee
$8,264
Profits / Employee
-$777,777
Market Cap
79.67M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ADVM News
- 1 day ago - Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewsWire
- 4 weeks ago - Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - GlobeNewsWire
- 4 weeks ago - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients - Seeking Alpha
- 4 months ago - Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - GlobeNewsWire